COSCIENS Biopharma Inc. sees slight gains amid ongoing operational updates.
This week, COSCIENS Biopharma Inc. (CSCI.TO) experienced a modest uptick in its stock price, closing at C$7.25, reflecting a weekly increase of 0.83%. Despite this positive movement, the company has not released any major news to explain the fluctuations in its stock.
Investor takeaway: As COSCIENS Biopharma navigates its operational challenges, investors should watch for upcoming financial results and strategic initiatives discussed in earlier announcements.
Advertisement
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$7.27M
52W high
$14.80
52W low
$3.30
1W change
+0.83%
Beta
1.89
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
63.3%
Annualized
90-Day Vol
335.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$8.73
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.75 | C$6.23 – C$9.64 |
| 60 trading days | C$8.22 | C$6.04 – C$11.20 |
| 90 trading days | C$8.73 | C$5.98 – C$12.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
COSCIENS Biopharma Inc. Posts 151.72% Year-to-Date Gain
Despite recent volatility, the stock has shown impressive year-to-date growth, suggesting potential long-term interest from investors.
Bull case
The company has reported improvements in its financial performance, including reduced net losses and better gross margins in recent quarters. These changes indicate that the company may be stabilizing its operations.
Bear case
COSCIENS Biopharma's stock has a high beta of 1.89, which means it can be quite volatile. Ongoing financial challenges, such as negative earnings and a management cease trade order, may raise concerns for investors.
Recent Price Action
Advertisement
COSCIENS Biopharma Inc. closed this week at C$7.25, reflecting a minor gain of 0.83% over the past week. The stock has shown a year-to-date increase of 151.72%, indicating a significant recovery from earlier lows.
Company News and Developments
This week, COSCIENS Biopharma did not release any new press announcements. However, the company has been active in reporting its financial results for previous quarters, focusing on improving operational efficiency and financial health. Recent reports highlight a reduction in net losses, which may boost investor confidence.
Technical Picture
Currently, COSCIENS Biopharma is trading below both its 50-day moving average of C$12.44 and its 200-day moving average of C$20.95, suggesting a bearish technical outlook. The stock has a 52-week range of C$3.30 to C$14.80, indicating it is currently at 34% of its range. With a beta of 1.89, the stock shows higher volatility compared to the broader market. Recent trading volume was 138 shares, which is 1.56 times the 20-day average volume of 1,040 shares, indicating increased investor activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
